Insider buying last 90 days
No open-market insider purchases were filed for ERAS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Erasca's week has been dominated by the termination of Chief Operating Officer Nicholas Chetwyn, which the company attributed to a leadership realignment. The departure sparked a stock drop of nearly 10% and prompted Pomerantz LLP, and separately Grabar Law Office, to launch investigations into potential securities fraud or breaches of fiduciary duty. Separately, Erasca and Tango Therapeutics initiated a Phase 1/2 study combining the oral PRMT5 inhibitor vopimetostat with the pan-RAS molecular glue ERAS-0015, and management is set to present at three investor conferences in November, including sessions from Guggenheim, Stifel, and Jefferies.
Shares closed at $15.61, up 8.3% on the day, sitting between the 50-day average of $15.03 and the 200-day average of $15.14. The GekkoIndex reads 56.3, placing the stock in the Neutral zone, down from a reading 5 points higher. Gekko Fair Value stands at $17.22, putting the current price 9.3% below that level.
Erasca reports earnings on 11 November 2026, just 116 days away and inside a typical 20-trading-day holding window; the last quarter showed an EPS of -0.14 versus a -0.11 estimate, with an average absolute reaction of 7.5% historically. Seasonality over the next 20 trading days has averaged -2.5% across 5 years, rising in 2 of them. Analyst coverage includes 5 buy and 2 hold ratings across 7 firms, with a consensus target of $24.11.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Erasca scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Averages disagree
Close $15.66 sits between the 50-day ($14.96) and 200-day ($15.26) averages, or the averages disagree.
See the chart53.8, Neutral
Reading 53.8 is in the Neutral zone.
See the GekkoIndex9.3% below
Price is 9.3% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 116 days
Next report Mar 11, 2027, 116 days away — outside a typical 20-trading-day hold.
See earnings−10.4% on average
From this point in the calendar, the next 20 trading days averaged −10.4% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Erasca closed at $15.66 on Nov 13, 2026, +490.9% over the past year, inside a 52-week range of $2.46 to $24.28.
Use the left and right arrow keys to read daily values.
Put ERAS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Erasca works on medicines for cancers linked to the RAS/MAPK pathway, developing them in clinical trials rather than selling approved treatments yet. It is best known for its pipeline of experimental drugs aimed at this biological pathway, including candidates meant to treat lung cancer, colorectal cancer, leukemia, solid tumors and a form of brain cancer. These compounds are taken orally, and one is designed to cross into the central nervous system to reach tumors there.
The company's efforts center on moving these drug candidates through development toward potential commercial use. Its work targets patients with specific cancer types tied to RAS/MAPK pathway activity, including those with advanced or metastatic disease and recurrent brain tumors, rather than a broader patient population.
Erasca was founded in 2018 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker ERAS.
Erasca’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.8, in the Neutral zone, down 7.3 points over five sessions.
Down 7.3 points over five sessions, from the Accumulation zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +0.1% | +2.9% | ||
| Accumulation | 198 | +3.5% | +7.5% | ||
| Neutral (current zone) | 396 | +2.1% | +13.7% | ||
| Distribution | 63 | +2.5% | +7.8% | ||
| Selling | 7 | Too few readings yet | |||
Average ERAS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Erasca trades 9.3% below Gekko Fair Value of $17.26, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Erasca shares are worth, recalculated every trading day.
$17.26
Gekko Fair Value, Nov 14, 2026
9.3% Undervalued
At the end of Aug 2026 the price was 19.3% below the estimate.
No open-market insider purchases were filed for Erasca, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ERAS in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ERAS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1of the funds Gekko tracks holds ERAS.
Erasca reports on Mar 11, 2027 (116 days away), and beat the EPS estimate in 3 of its last 8 reports.
Mar 11, 2027
116 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 12, 2026 | −$0.14 est −$0.11 | — | −2.5% |
| May 11, 2026 | −$0.60 est −$0.23 | — | +2.6% |
| Mar 12, 2026 | −$0.10 est −$0.11 | — | −12.1% |
| Nov 12, 2025 | −$0.11 est −$0.11 | — | +7.6% |
| Aug 12, 2025 | −$0.12 est −$0.12 | — | +9.5% |
| May 13, 2025 | −$0.11 est −$0.12 | — | −8.6% |
| Nov 12, 2024 | −$0.11 est −$0.17 | — | −8.4% |
| Aug 12, 2024 | −$0.29 est −$0.18 | — | +8.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Erasca is $24.11, +54.0% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Piper Sandler | $22 | +40.5% |
| Nov 13 | H.C. Wainwright | $22 | +40.5% |
| Nov 13 | Bank of America Securities | $20 | +27.7% |
| Oct 26 | Bank of America Securities | $20 | +27.7% |
| Oct 19 | Bank of America Securities | $20 | +27.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Erasca averaged −10.4% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.4% | 2 of 5 |
| Next 10 trading days | −8.0% | 2 of 5 |
| Next 15 trading days | −6.2% | 2 of 5 |
| Next 20 trading days | −10.4% | 1 of 5 |
| Next 30 trading days | −9.7% | 2 of 5 |
For scale, ERAS’s typical 20-trading-day move in either direction is about 12.5%.
Erasca’s market cap is $5.48B and revenue of $0 over the last twelve months.
Coverage of Erasca this week reads neutral: 0 positive, 5 neutral and 3 negative headlines.
Erasca’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Erasca’s market cap is $5.48B at the Nov 13, 2026 close of $15.66, with 349.8M shares outstanding.
The consensus analyst 12-month price target for Erasca is $24.11, +54.0% from the last close. Of the 6 firms that rated the stock in the last 90 days, 4 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Erasca is undervalued: the Nov 13, 2026 close of $15.66 is 9.3% below Gekko Fair Value of $17.26. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Erasca is expected to report on Mar 11, 2027 (116 days away). Analysts expect earnings of −$0.13 per share. Erasca beat the earnings estimate in 3 of its last 8 reports, moving 7.5% on average across the report.
Erasca’s 52-week high is $24.28 and its 52-week low is $2.46; it closed at $15.66 on Nov 13, 2026, +490.9% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 2 as mixed (trend and gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.